Clinical Trials Logo

Filter by:
NCT ID: NCT05468970 Recruiting - Clinical Features Clinical Trials

Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Start date: August 3, 2022
Phase:
Study type: Observational

It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.

NCT ID: NCT05468905 Recruiting - Alzheimer Disease Clinical Trials

China Longitudinal Aging and Cognitive Impairment Study

CLACIS
Start date: January 10, 2021
Phase:
Study type: Observational

This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.

NCT ID: NCT05468502 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Start date: October 10, 2022
Phase: Phase 1
Study type: Interventional

Main purpose -To explore the safety and tolerance of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF). Secondary purpose - To explore the preliminary efficacy of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF), and to recommend the appropriate dose of cell therapy for subsequent clinical studies. - To explore the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of idiopathic pulmonary fibrosis (IPF). This study adopts a clinical research design of multi center, single dose and increasing dose. 18 qualified IPF subjects will be included in this study.

NCT ID: NCT05468307 Recruiting - Clinical trials for Treatment Side Effects

Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with cyclophosphamide.

NCT ID: NCT05468242 Recruiting - Clinical trials for Stage III Non-small Cell Lung Cancer

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.

NCT ID: NCT05468190 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Start date: July 17, 2022
Phase: Phase 1
Study type: Interventional

As a phase I clinical research,this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

NCT ID: NCT05468177 Recruiting - Colonic Neoplasms Clinical Trials

Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer

CIFOXRC
Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

We plan to evaluate the efficacy and safety of cetuximab combined with anti-PD-1 and mFOLFOX6 in the treatment of RAS/BRAF WT locally advanced or metastatic right colon cancer

NCT ID: NCT05467943 Recruiting - Clinical trials for Relapsed/Refractory Follicular Lymphoma With EZH2

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Start date: July 29, 2022
Phase: Phase 2
Study type: Interventional

Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat

NCT ID: NCT05467189 Recruiting - Cancer Clinical Trials

Antineoplastic Drugs in Elderly Patients

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

NCT ID: NCT05466903 Recruiting - Colonic Polyp Clinical Trials

Prospective, Randomized, Parallel Clinical Controlled Study of Early Diet Opening on Postoperative Gastrointestinal Hemorrhage in Patients With Colonic Polyps

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Currently, hemorrhage remains the most common postoperative complication in patients with colon polyps, with an incidence of approximately 1.5%. The main reasons for postoperative hemorrhage are: the patient's own condition, the nature of the polyp and the operation. The number of patients treated for colon polyps has increased, postoperative care is confusing, medical resources are wasted, and the time span for postoperative diet recovery is large. However, studies on the effect of postoperative dietary recovery timing on postoperative polyp bleeding are rare.